127 related articles for article (PubMed ID: 17476354)
1. Geranylgeranyltransferase I as a target for anti-cancer drugs.
Philips MR; Cox AD
J Clin Invest; 2007 May; 117(5):1223-5. PubMed ID: 17476354
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
4. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
Sjogren AK; Andersson KM; Liu M; Cutts BA; Karlsson C; Wahlstrom AM; Dalin M; Weinbaum C; Casey PJ; Tarkowski A; Swolin B; Young SG; Bergo MO
J Clin Invest; 2007 May; 117(5):1294-304. PubMed ID: 17476360
[TBL] [Abstract][Full Text] [Related]
5. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Liu M; Sjogren AK; Karlsson C; Ibrahim MX; Andersson KM; Olofsson FJ; Wahlstrom AM; Dalin M; Yu H; Chen Z; Yang SH; Young SG; Bergo MO
Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6471-6. PubMed ID: 20308544
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
Kim KW; Chung HH; Chung CW; Kim IK; Miura M; Wang S; Zhu H; Moon KD; Rha GB; Park JH; Jo DG; Woo HN; Song YH; Kim BJ; Yuan J; Jung YK
Oncogene; 2001 Jan; 20(3):358-66. PubMed ID: 11313965
[TBL] [Abstract][Full Text] [Related]
7. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
Trueblood CE; Ohya Y; Rine J
Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
[TBL] [Abstract][Full Text] [Related]
8. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
9. Targeted reengineering of protein geranylgeranyltransferase type I selectivity functionally implicates active-site residues in protein-substrate recognition.
Gangopadhyay SA; Losito EL; Hougland JL
Biochemistry; 2014 Jan; 53(2):434-46. PubMed ID: 24344934
[TBL] [Abstract][Full Text] [Related]
10. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Reid TS; Terry KL; Casey PJ; Beese LS
J Mol Biol; 2004 Oct; 343(2):417-33. PubMed ID: 15451670
[TBL] [Abstract][Full Text] [Related]
11. Restricted substrate specificity for the geranylgeranyltransferase-I enzyme in Cryptococcus neoformans: implications for virulence.
Selvig K; Ballou ER; Nichols CB; Alspaugh JA
Eukaryot Cell; 2013 Nov; 12(11):1462-71. PubMed ID: 24014765
[TBL] [Abstract][Full Text] [Related]
12. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
16. Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes.
Kelly R; Card D; Register E; Mazur P; Kelly T; Tanaka KI; Onishi J; Williamson JM; Fan H; Satoh T; Kurtz M
J Bacteriol; 2000 Feb; 182(3):704-13. PubMed ID: 10633104
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
18. Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity.
Hartman HL; Hicks KA; Fierke CA
Biochemistry; 2005 Nov; 44(46):15314-24. PubMed ID: 16285735
[TBL] [Abstract][Full Text] [Related]
19. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
20. Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.
Yang SH; Chang SY; Tu Y; Lawson GW; Bergo MO; Fong LG; Young SG
J Lipid Res; 2012 Jan; 53(1):77-86. PubMed ID: 22039581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]